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Summary  
 
Background: Stress is defined as a state of threat to homeostasis and stress response 
involves the activation of behavioral and physiological systems that promote survival. 
Indeed, stress response leads to the activation of the hypothalamic-pituitary-adrenal 
axis, which through the release of glucocorticoids, exerts determinant effects upon 
environment adaptation and energy metabolism. Prolongation of the stress response, as 
in chronic stress, can have detrimental effects, especially on whole body metabolism.  
The metabolic syndrome can be described as a cluster of metabolic abnormalities that 
increase the risk of heart disease and type 2 diabetes. Several studies suggest that 
intense and chronic reactivity to stress can be a predictor of metabolic syndrome. 
Objective: This article reviews the state of the art regarding the association between 
glucocorticoid actions and both obesity and insulin resistance, two main features of the 
metabolic syndrome.  
Methods: A methodological assessment of the literature on PubMed and SciELO 
databases was conducted by using the following terms: stress, metabolic syndrome, 
glucocorticoids, obesity, insulin resistance, hypothalamic-pituitary-adrenal-axis and 
11β-hydroxysteroid dehydrogenase. 
Results: Chronic stress, mainly through hypothalamic-pituitary-adrenal axis 
dysregulation, promotes the accumulation of visceral fat. Reciprocally, obesity 
promotes a systemic low-grade inflammation state, mediated by increased adipokine 
secretion, which can chronically stimulate and disturb stress system. 11β-
hydroxysteroid dehydrogenase appears as a fascinating entity that multiplies the 
complexity of glucocorticoid system biology. 
Conclusions: Given the strong evidences linking glucocorticoids release, obesity and 
type 2 diabetes, a better understanding of the mechanisms underlying this link might be 
useful for prevention and treatment of the metabolic syndrome. 
 
Keywords:  
Stress; Glucocorticoids; Obesity; Insulin resistance; Metabolic Syndrome; 11β-
Hydroxysteroid Dehydrogenase.  
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Resumo 
 
Introdução: O stresse pode ser definido como um estado de ameaça à homeostasia e a 
resposta ao stresse envolve a ativação de sistemas comportamentais e fisiológicos que 
visam a sobrevivência do indivíduo. A resposta ao stresse conduz à activação do eixo 
hipotálamo-hipófise-suprarrenal, que, através da libertação de glicocorticóides, exerce 
efeitos determinantes na adaptação ao ambiente e no metabolismo energético. O 
prolongamento da resposta ao stresse, como no stresse crónico, pode acarretar efeitos 
adversos, particularmente no metabolismo. A síndrome metabólica pode ser definida 
como uma agregação de alterações metabólicas que aumentam o risco de doença 
cardiovascular e diabetes tipo 2. Vários estudos sugerem que a reatividade intensa, e 
sustentada, ao stresse pode ser um preditor de risco para síndrome metabólica. 
Objetivo: Este artigo revê o estado da arte relativamente à associação entre as ações dos 
glicocorticóides e a obesidade e a resistência à insulina, dois dos principais 
componentes da síndrome metabólica. 
Métodos: Foi conduzida uma revisão da literatura nas bases de dados PubMed e 
SciELO usando as seguintes palavras-chave: stresse, síndrome metabólica, 
glicocorticóides, obesidade, resistência à insulina, eixo hipotálamo-hipófise-suprarrenal 
e 11β-hidroxiesteróide desidrogenase. 
Resultados: O stresse crónico, principalmente através da desregulação do eixo 
hipotálamo-hipófise-suprarrenal, promove a acumulação de gordura visceral. Ao mesmo 
tempo, a obesidade promove um estado inflamatório sistémico de baixo grau, mediado 
por alterações na secreção de adipocinas, que cronicamente podem estimular e perturbar 
o sistema de stresse. A 11β-hidroxiesteróide desidrogenase é uma entidade fascinante 
que amplia a complexidade da biologia do sistema glicocorticóide. 
Conclusões: Dadas as fortes evidências que ligam a libertação de glicocorticóides, a 
obesidade e a diabetes tipo 2, um conhecimento mais aprofundado sobre os mecanismos 
envolvidos nesta associação pode ser útil na prevenção e tratamento da síndrome 
metabólica.  
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Palavras chave: Stresse; Glicocorticóides; Obesidade; Resistência à insulina; Síndrome 
Metabólica; 11β-hidroxiesteróide desidrogenase. 
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Abbreviations 
 
11β-HSD1 - 11β-Hydroxysteroid Dehydrogenase Type 1 
11β-HSD2 - 11β-Hydroxysteroid Dehydrogenase Type 2  
ACTH – Adrenocorticotropic hormone 
AMPK – 5-adenosine monophosphate-activated protein kinase   
AVP – Vasopressin 
BMI – Body mass index  
CBG - Corticosteroid-binding globulin  
CRH – Corticotropin-releasing hormone 
G6Pase - Glucose-6-phosphatase 
GC - Glucocorticoids 
GR – Glucocorticoid receptor 
H6PDH - Hexose-6-phosphate dehydrogenase  
HPA - Hypothalamic-pituitary-adrenal 
IL-1 – Interleukin-1 
IL-6 - Interleukin-6 
MS –Metabolic Syndrome 
MR - Mineralocorticoid receptor 
NADPH - Nicotinamide adenine dinucleotide phosphate 
NPY - Neuropeptide Y 
PEPCK – phosphoenolpyruvate carboxykinase 
PPAR - Peroxisome proliferator-activated receptor 
TAG - Triglycerides  
TNFα – Tumor necrosis factor α 
6 
 
Introduction 
Stress is defined as a state of threatened homeostasis 
1, 2
, and comprises a complex 
repertoire of physiologic and behavioral responses that aim to restore the challenged 
body equilibrium 
3
. The hypothalamic-pituitary-adrenal (HPA) axis and the central and 
peripheral components of the autonomic nervous system are responsible for crucial 
functions of the stress system 
4
. Acute activation of stress reaction leads to a cluster of 
time-limited, behavioral and physical changes that are normally adaptive and aim to 
improve the chances of individuals to survive 
4, 5
. Inadequate, excessive, and/or 
prolonged  reactions to stress may lead to disease 
5
. Chronic stress, a prolonged threat to 
homeostasis by persistent or frequently repeated stressors, is an important aspect of 
daily life leading to the development of a wide range of diseases and syndromes 
4
. In 
fact, long exposure to stress can disrupt the pathways involved in metabolism, growth, 
reproduction, immunity, personality and behavior development 
1
. 
The metabolic syndrome (MS) can be described as a cluster of metabolic abnormalities, 
in which fat accumulation appears to play a central role and has a thigh relationship 
with type 2 diabetes 
6
. Obesity has become recognized as one of the major health 
problems threatening the world today with a strong and deleterious impact on health 
status and health-care costs 
7-10
. To allow humans to cope with periods of starvation, 
they were genetically programed to accumulate high amounts of energy. However, 
nowadays modern lifestyles offer open access to food and promote sedentary habits, 
leading to a progressive cycle of overeating and weight gain 
11
. The prevalence of type 2 
diabetes mellitus is expected to get worse in the next decades 
11
 and is an important 
cause of mortality and morbidity worldwide 
12
. It has been raised the hypothesis that an 
adverse psychosocial environment contributes to development of obesity and type 2 
diabetes 
13, 14
. In fact, intense stress reactivity and an abnormal recovery after stress 
predict MS development 
15
. Long exposure to psychological stress may impair the 
capacity of the organism to maintain a biological balance and thus disrupt homeostasis 
16
, causing adverse metabolic effects. Several studies have shown a significant 
association between glucocorticoids (GC), visceral fat, type 2 diabetes and MS 
3,
 
17,
 
18
. 
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Methods  
This review will discuss the link between GC metabolic effects and the development of 
obesity, insulin resistance and the MS. A methodological assessment of the literature on 
PubMed and SciELO databases was conducted without setting limits for year 
publication but selecting both English and Portuguese papers with full text availability. 
The following terms were used for this review: stress, metabolic syndrome, 
glucocorticoids, obesity, insulin resistance, hypothalamic-pituitary-adrenal-axis and 
11β-hydroxysteroid dehydrogenase. 
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Stress and mediators of stress response - HPA axis 
The HPA axis is important in maintaining a dynamic equilibrium or homeostasis in a 
constantly changing environment 
4,
 
19
. The paraventricular nucleus of the hypothalamus 
contains neuroendocrine neurons that synthesize and secrete vasopressin (AVP) and 
corticotropin-releasing hormone (CRH). CRH and AVP are released from 
neurosecretory nerve terminals at the median eminence. CRH is transported to the 
anterior pituitary through the portal blood vessel system of the hypophyseal stalk and 
AVP is transported by axonal transport to the posterior pituitary. There, CRH and AVP 
act synergistically to stimulate the secretion of stored adrenocorticotropic hormone 
(ACTH) from corticotrope cells. ACTH is transported by blood to the adrenal gland, 
where it rapidly stimulates the biosynthesis of GC 
4, 20,
 
21
. GC, in turn, inhibit CRH at 
the hypothalamic level, and interfere with ACTH-secretion in the anterior pituitary, 
thereby establishing a regulatory feedback loop 
22
. The activity of this endocrine system 
is characterized by a robust circadian rhythm with cortisol levels peaking in the early 
morning hours around the time of awakening and being lowest around midnight 
23
. 
Diurnal variations are modulated by changes in lighting, feeding schedules, and 
physical activity, and are disrupted in face of a stressor 
4
. Inflammatory mediators can 
also be secreted in response to different stressors and can activate the HPA axis 
24
. For 
instance, tumor necrosis factor-α (TNFα), interleukin-1 (IL-1) and interleukin-6 (IL-6) 
are mainly present in states of chronic inflammatory stress and can activate HPA axis 
24
. 
GC are present in the systemic circulation mainly bound to corticosteroid-binding 
globulin (CBG) (approximately 90%) and also, to albumin (4–5%) 23. Only 5–6% of the 
total circulating GC remain in an unbound state and, thus, biologically active 
25
. CBG 
may have, either a buffer function blunting elevations of free cortisol during a secretory 
peak or a reservoir role maintaining cortisol pool during times of reduced secretion 
26
. 
GC exert an inhibitory feedback action in the stress response system, which is 
fundamental in limiting the duration of the total GC tissue exposure, thus minimizing 
their catabolic, adipogenic, antireproductive, and immunosuppressive effects 
4
. GC 
exert their actions by binding to two types of intracellular receptors: the glucocorticoid 
receptor (GR) which responds to high levels of GC and the mineralocorticoid receptor 
(MR) responding to low levels of GC 
22,
 
27
. GC modulate the expression of a wide-range 
of genes in a DNA-dependent and independent manner 
4,
 
22,
 
23,
 
28
. It is of note that 
9 
 
numerous genes encoding important proteins that are directly or indirectly implicated in 
several metabolic pathways are rigorously regulated by GC (Table 1) 
4,
 
23
.  
11β-Hydroxysteroid Dehydrogenase (11β-HSD) catalyzes the interconversion of 
inactive cortisone to active cortisol, or vice-versa 
23,
 
29
. 11β-Hydroxysteroid 
Dehydrogenase type 2 (11β-HSD2) predominates in renal tubules protecting the MR 
from excessive stimulation by cortisol. It has also been identified in the colon, salivary 
glands and placenta 
25
. Apparent mineralocorticoid excess syndrome results from 
defective 11β-HSD2. Its deficiency allows cortisol to bind to MR inducing sodium 
retention, hypokalemia and hypertension 
30,
 
31
. 11β-Hydroxysteroid Dehydrogenase type 
1 (11β-HSD1) which is mostly expressed in liver, fat, gonadal tissue and central 
nervous system, is believed to function as a reductase generating active cortisol at a 
prereceptor level, thus enhancing GC receptor activation 
32
. The co-localization of 11β-
HSD1 with Hexose-6-phosphate dehydrogenase (H6PDH) has an important role in 
providing nicotinamide adenine dinucleotide phosphate (NADPH) as cofactor to drive 
the direction to 11β-HSD1 reductase 25. 
 
Physiological effects of glucocorticoids  
GC are the final mediators of HPA axis activation, playing a key role in modulating 
immunological and inflammatory responses, energy metabolism and cardiovascular 
homeostasis and general body responses to stress 
25
. In order to face threats imposed by 
stressors, generalized responses are activated towards the restoration of homeostasis. 
Behavioral adaptation includes increased arousal, euphoria and cognition, enhanced 
analgesia, and sleep inhibition. Physical adaptation includes increases in cardiovascular 
tone, respiratory rate, and metabolism. The activation of HPA axis promotes a 
redirection of energy, in order to deliver oxygen and nutrients to organs and tissues 
involved in the functional system of adaptation. In the meantime, other non-emergent 
functions, such as digestion, reproduction, growth, and overall immunity, are 
temporarily suppressed 
4,
 
32,
 
33
 . All these acute effects increase the capacity for 
generation of energy over a limited period of time improving the ability to ‘fight or 
flight’ 32. GC induce lipolysis, even though they favor abdominal and dorsocervical fat 
accumulation 
28
. Given that GC promote delivery of fuel to skeletal muscle, the increase 
10 
 
in triglycerides (TAG) stores in adipose tissue in clinical conditions with GC excess 
appears paradoxical. This paradox probably reflects the combination of elevated GC 
levels concomitantly with elevated insulin levels in individuals who are able to ingest 
unrestricted energy without consuming it – for instance, through physical exercise. In 
these circumstances, fatty acid esterification predominates over lipolysis and, combined 
with stimulation of pre-adipocyte differentiation, promotes fat accumulation 
32,
 
34
. 
GC increase hepatic gluconeogenesis and decrease glucose uptake and insulin 
sensitivity, thus favoring hyperglycemia. In order to provide amino acids as an 
additional substrate for oxidative pathways, GC cause protein degradation at multiple 
tissues such as muscle, bone, and skin. GC also antagonize the anabolic actions of 
growth and thyroid hormones, insulin, and sex steroids on their target tissues 
4,
 
33
. 
Globally, stress response is responsible for a shift of normal metabolism, favoring a 
catabolic state which returns to normal after stress removal. Chronic exposure to stress, 
however, can be potentially damaging, as long exposure to GC can dysregulate multiple 
metabolic pathways leading to a progressively increase in visceral adiposity, 
hyperglycemia, dyslipidemia, hypertension and insulin resistance 
4,
 
33
. Elevated 
circulating GC levels also result in myopathy, osteopenia or osteoporosis, osteonecrosis, 
mental disturbances, increased susceptibility to infections and infertility 
32,
 
33,
 
35
. GC 
actions in the central nervous system are complex 
33
. GC affect the capacity to 
apprehend sensations and establish suitable reactions to stimuli 
36
, modulate behavior 
and humor and interfere with memory retention 
5
. Short-term changes in immunological 
function may be valuable, preventing the damage caused by sustained exposure to 
various cytokines 
4,
 
5,
 
37
. 
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Metabolic Syndrome  
The MS is a cluster of metabolic abnormalities that increase the risk for type 2 diabetes 
mellitus and cardiovascular disease. It can be defined as a state of disturbed metabolic 
homeostasis characterized by the combination of central obesity, insulin resistance, 
dyslipidemia, and hypertension 
20,
 
28,
 
38-40
. The worldwide incidence of both obesity and 
MS has been significantly rising in the last decades, threatening to become the new 
epidemic of this century. In fact, currently MS affects ¼ of the adult Portuguese 
population 
41
. It is noteworthy to mention that these clinical conditions often show a 
relationship with indices of stress 
42
. Although obesity per se is not a required feature 
for the diagnosis of MS, several evidences suggest that both visceral obesity and insulin 
resistance have a key role in the pathogenic mechanisms underlying the MS 
13,
 
35,
 
43
. 
The distribution of fat seems to be a powerful predictor of cardiometabolic disease 
44
. 
Many prospective studies have shown that central obesity is more often correlated to the 
features of MS 
9,
 
43,
 
45
. This pathophysiologic relationship is consistent with the 
emphasis on waist measurement for MS criteria rather than body mass index (BMI), as 
an indicator of obesity-related cardiovascular risk 
43
. In fact, even in normal-weight 
subjects, increased abdominal circumference is associated with increased risk of 
cardiovascular disease 
46
. 
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Clinical association between hypercortisolism and the metabolic syndrome  
The similarities between the clinical features of Cushing syndrome and those of MS 
raised the hypothesis that MS is associated with GC excess 
15,
 
23,
 
33,
 
47
. Cortisol excess 
has been implicated in the development of diabetes and obesity, highlighting the role of 
psychological stress on both conditions (Figure 1) 
48-50
. Indeed, human studies have 
documented that abdominal obesity and its metabolic comorbidities are significantly 
correlated with stress-related conditions such as adverse life events, psychological 
disturbances, and psychosocial problems 
3
. In fact, the individual inability to cope with 
long-term environmental adverse stressful events has been related to HPA axis 
hyperactivation in obesity, particularly the visceral phenotype 
15
. Chronic work stress 
also seems to predict general and central obesity during midlife 
1
. Prolonged and 
nonremitting stress may result in chronic hyperactivation of the HPA axis with resulting 
sustained GC release 
42,
 
51
, which can progressively cause visceral fat accumulation and 
insulin resistance 
48,
 
49
. In line with this, patients with MS seem to have HPA axis 
hyperactivity and a functional hypercortisolism 
23,
 
52
. On the contrary, in obese 
individuals, the circulating GC levels have been reported as normal or even low 
2,
 
53-57
. 
Several hypotheses can explain an abnormal secretion of cortisol in obesity. Firstly, the 
presence of a primary neuroendocrine abnormality can cause an irregular central drive 
to CRH, ACTH and cortisol. Second, an altered peripheral metabolism of cortisol due to 
dysregulation of 11β-HSD1 can also explain normal or low cortisol concentrations in 
obesity 
58
. On the other hand, it has been suggested that cortisol production rate may 
increase as the amount of visceral fat enlarges 
59
, however as said before in most cases 
its plasma concentrations are normal or even lower. This might be partly explained by 
enhanced metabolic clearance of cortisol 
28,
 
55
, due to a combination of enhanced 5α-
redutase activity and impaired regeneration of cortisol from cortisone by 11β-HSD1 in 
liver, which results in the increase of cortisol urinary metabolites excretion 
58
. In 
accordance with this, it has been shown that patients with obesity and MS show 
increased urinary excretion of free cortisol and its metabolites 
28
. Interestingly, the 
excretion of urinary free cortisol correlates with anthropometric parameters of visceral 
fat distribution 
58
. Overall, there appears to be a hyperactivity of the HPA axis in 
response to stress in patients with visceral obesity 
3,
 
28,
 
55
, which is in accordance with 
results that show a higher release of cortisol after stimulation with ACTH and greater 
13 
 
ACTH release after CRH infusion 
2,
 
59
. Moreover, chronically active HPA axis has an 
inadequate suppression by dexamethasone 
60
. Several studies have shown that in obesity 
different stimulus such as neuropeptides, psychological stress and mixed meal tests 
induced an hyperactivation of HPA axis 
15
. Individuals that show elevated levels of 
cortisol in response to perceived stress show a higher association with central fat mass 
and signs of MS 
55,
 
61
. Animal studies demonstrated that cynomolgus monkeys 
subjected to high stress levels comparably to controls secreted higher amounts of GC 
and were less sensitive to their negative feedback 
51
. Another study reported that these 
animals undergoing physical and psychological stress presented higher basal cortisol 
levels and increased cortisol release after ACTH stimulation, which was associated with 
greater visceral fat accumulation 
42
. In the adipose tissue, lipids are stored as TAG. GC 
increase lipolysis in adipocytes as a result of increased transcription and expression of 
the lypolytic proteins adipose triglyceride lipase and hormone-sensitive lipase, 
increasing the amount of fatty acids in circulation, which, in turn, contribute to 
triglyceride accumulation in other tissues 
62
. In liver, GC increase the expression of fatty 
acid synthase increasing lipid production, thus favoring hepatic steatosis. GC also 
promote the secretion of lipoproteins 
23
. TAG in circulation, as components of both very 
low-density lipoproteins and chylomicrons, when hydrolyzed release fatty acids that can 
be taken up by the surrounding tissues for use or storage, mainly in liver, muscle and 
central adipocytes 
19
. GC promote the differentiation of adipose stromal cells to mature 
adipocytes, increasing visceral fat accumulation 
19,
 
63
 and redistributing adipose tissue 
from peripheral to central depots, and increasing the size and number of fat cells 
28,
 
56
. 
Adenosine monophosphate activated protein kinase (AMPK) is a sensor of cellular 
energy status and is activated in response to a decrease of this state. When activated, 
AMPK stimulates appetite in the hypothalamus and switches anabolic into catabolic 
pathways, such as glycolysis and fatty acid oxidation. GC inhibit the AMPK system 
thus contributing to central fat deposition 
64
. GC increase caloric and dietary fat intake 
19
 and suppress thermogenesis 
15
.  
Growing evidence suggests that there is a relationship between type 2 diabetes and 
chronic stress disorders 
1
. In fact, circulating cortisol concentrations are higher in people 
with glucose intolerance and type 2 diabetes 
65
. GC raise blood glucose levels through 
several mechanisms 
62
. GC impair the insulin-dependent glucose uptake in peripheral 
14 
 
tissues 
66
, enhance glucose production in the liver and inhibit insulin secretion from 
pancreatic β-cells [51]. Thus, cortisol excess can be correlated with diabetes mellitus in 
clinical settings 
62
. Insulin stimulates translocation of the GLUT4 glucose transporters 
from intracellular compartments to plasma membrane, increasing the rate of glucose 
utilization 
66
, however this action is inhibited by high levels of GC 
23
. In insulin 
sensitive tissues, such as liver and skeletal muscle, GC also impair pathways involved in 
insulin receptor activation 
3,
 
62,
 
67
. GC promote gluconeogenesis by stimulating the 
expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(G6Pase), the rate-limiting enzymes of this pathway, resulting in increased hepatic 
glucose output and hyperglycemia 
23,
 
62
. GC decrease GLUT2 expression in pancreatic 
β-cells and impair calcium disposal on insulin secretory process, thus affecting its 
secretion 
23,
 
68
. 
Obesity seems to be implicated in the development of insulin resistance 
43,
 
46
. In fact, 
pathophysiological accumulation of lipids in liver has been identified as an independent 
risk factor for insulin resistance and MS 
22
. Free fatty acids inhibit insulin secretion by 
pancreas and decrease glucose uptake 
69
. GC release increases lipolysis generating free 
fatty acids into the circulation, which in turn impair insulin signaling pathways 
downstream of its receptor, thus promoting insulin resistance 
46,
 
70
. In humans, the 
administration of dexamethasone decreases glucose oxidation, which can be due to an 
increase of free fatty acids plasmatic levels 
66
. Thus, insulin resistance can result from 
an excess of visceral fat 
46,
 
71
. On the other hand, insulin resistance impairs lypogenesis, 
thus increasing the plasmatic levels of free fatty acids, creating a vicious circle 
70
. 
Adipokines play an important role on fat accumulation and insulin resistance 
46,
 
70
. 
Adiponectin modulates a number of metabolic processes, including glucose homeostasis 
and fatty acid oxidation. It promotes insulin sensitivity and is negatively regulated by 
GC 
28
. Hypoadiponectinemia is an independent risk factor for developing MS and type 
2 diabetes mellitus 
72
. Leptin plays a key role in regulating both energy intake and 
metabolism, and its circulating levels are directly proportional to body fat. Activation of 
hypothalamic leptin receptors suppresses appetite, induces satiety and increases energy 
expenditure 
73
. High sustained concentrations of leptin released from adipose tissue 
result in desensitization of leptin receptor leading to leptin resistance 
70,
 
74
. Unusually 
high circulating leptin levels and low adiponectin levels are generally exhibited by 
15 
 
patients with obesity, insulin resistance and MS 
46
. Visfatin is a recently discovered 
adipokine with insulin-mimetic properties 
43
. ACTH reduces the expression of both 
visfatin and adiponectin, thus promoting a temporary state of insulin resistance. 
Neuropeptide Y (NPY) release in response to HPA axis activation seems to promote 
abdominal fat storage. GC stimulate NPY hypothalamic secretion and up-regulate the 
NPY Y2 receptor in visceral fat. NPY increases food intake and storage of energy as fat 
and NPY Y2 receptor activation stimulate fat angiogenesis, proliferation and 
differentiation of new adipocytes 
74
. 
GR signaling plays a significant role in metabolic regulation, and defects in this 
signaling pathway have been implicated in the development of several phenotypes of 
MS 
75
. In fact, insulin resistance is associated with increased GR expression in skeletal 
muscle 
62,
 
76,
 
77
. Several polymorphisms related to the HPA axis have been associated 
with HPA abnormal function and the development of MS 
34,
 
57,
 
74,
 
78
. Chronic stress 
disorders are commonly associated with behavioral changes which lead to weight gain 
and metabolic abnormalities. Chronic stress seems to promote unhealthy behaviors such 
as a sedentary lifestyle, alcohol consumption, smoking and overeating 
1
. Stress system 
affects the hypothalamic appetite-satiety centers therefore disturbing food intake 
4
. The 
relationship between stress and food ingestion has been extensively investigated but has 
led to conflicting results 
79,
 
80
. Increasing food intake during stress diminishes HPA axis 
response to stressors 
81
, which might explain why various individuals overeat when 
exposed to stress. Food ingestion to relieve anxiety is a harmful coping strategy and can 
lead to undesirable weight gain and obesity 
61
. On the other hand, acute stress may be 
accompanied by a decrease on food consumption. Indeed, acute elevations of CRH can 
cause anorexia and stimulate energy expenditure. As mentioned before, NPY increases 
food intake and storage of energy as fat, and acute stress inhibits NPY release 
4
. On the 
contrary, chronic stressful situations have the opposite effect and people experiencing a 
high stress reactivity tend to have a greater caloric intake, preferably dense calories 
61
. 
In fact, long-term exposure to circulating GC seems to enhance consumption of high fat 
and highly palatable foods 
74,
 
79-81
 . GC also decrease energy expenditure 
4
 and diminish 
signs of satiety 
61
. A high caloric intake is a mechanism that seems natural in response 
to fasting. However, this is not the case of psychological stress conditions, in which 
food is used rather to relief anxiety than to overcome fasting 
19,
 
81,
 
82
.   
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11β-HSD1 role  
Tissue-specific dysregulation of cortisol metabolism is involved in the complex 
pathophysiology of obesity and the MS 
56,
 
83
. In fact, 11β-HSD1 expression positively 
correlates with obesity and insulin resistance 
56
. As mentioned before, circulating GC 
concentrations are occasionally abnormal in human obesity, however locally enhanced 
responsiveness to GC has also been implicated in MS development 
1,
 
28,
 
62,
 
77,
 
78,
 
84
. 
Obese individuals have a tissue-specific 11β-HSD1 dysregulation 58, 65 in which 11β-
HSD1 activity is found selectively increased in visceral fat depots and decreased in liver   
32,
 
52,
 
85
. The relationship between the 11β-HSD1 function and metabolic disorders has 
been well established by studies using genetically modified rodent models. In fact, 
upregulation of 11β-HSD1 expression selectively in adipose tissue leads to a model of 
MS in mice 
62,
 
78
. Mice with a similar degree of 11β-HSD1 overexpression in liver show 
an attenuated MS profile without visceral obesity 
52
. On the contrary, knockout mice 
lacking 11β-HSD1 exhibit protection for MS features 31, 46, 52, 53, 65. Peroxisome 
proliferator-activated receptors (PPAR) are a group of nuclear receptor proteins 
86,
 
87
 
involved in adipocyte differentiation and fat redistribution to the periphery 
53
. 11β-
HSD1 knockout mice show higher expression of PPAR-ϒ receptor in all adipose tissue 
depots 
77
.  
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Obesity as a chronic inflammatory state  
In recent years, it has become clear that obesity is a state of chronic low-grade 
inflammation. The association between insulin resistance and the other components of 
the MS can be a consequence of their common outcomes as low-grade inflammation 
states 
45,
 
46
. Adipose tissue releases cytokines that initiate a state of low-grade 
inflammation resulting in the metabolic, hemodynamic and vascular consequences of 
this state 
45,
 
71
. The uninterrupted release of these pro-inflammatory adipokines is a 
chronic stimulus for HPA axis activation, creating a vicious cycle, in which 
hypercortisolemia promotes adipocyte growth and vice versa 
4
. The pro-inflammatory 
cytokines, TNFα, IL-1 and IL-6 act synergistically activating HPA axis and increasing 
11β-HSD1 expression in adipose tissue 23, 28, 53. IL-6 concentrations have a strong 
correlation with visceral obesity 
88
 and are associated with insulin resistant 
71,
 
89
. There 
is a positive association between TNFα concentrations and BMI, and this cytokine 
seems to be implicated in insulin resistance development 
46,
 
59,
 
71,
 
73,
 
90
. 
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Glucocorticoids inhibitors as potential therapeutic targets  
To date, no single agent can ameliorate the underlying causes of MS 
46
. Additional 
research is needed for novel agents to effectively treat the multiple abnormalities of this 
syndrome 
40
. Antagonizing GC action has been taken as an approach to treat some of 
the MS features 
23
, leading to decreases in adiposity, glucose intolerance and insulin 
resistance 
67
, lowering fasting blood glucose and normalizing its postprandial levels 
32,
 
76
. However, long- term systemic treatment with a GR antagonist may not be a viable 
option, since it can excessively activate the HPA axis causing adrenal hyperplasia and 
undesirable increase in cortisol, androgens and mineralocorticoids 
62,
 
77,
 
78
. On the other 
hand, selective 11β-HSD1 inhibitors have shown considerable potential for MS 
treatment 
28,
 
91
. Over the past years, clinical studies have been conducted for several 
11β-HSD1 inhibitors 52, 62, 83, 92-94. The ability to decrease intracellular cortisol levels in 
liver and adipose tissue, without altering circulating cortisol concentrations or responses 
to stress, is an exciting therapeutic strategy for obesity, type 2 diabetes mellitus and MS 
treatment. In fact, these drugs have been shown to ameliorate metabolic abnormalities, 
by improving lipid profile, insulin sensitivity, promoting glucose tolerance and blocking 
adipogenesis 
28,
 
67,
 
68,
 
83,
 
85,
 
91-93, 95. However, there are some concerns regarding the use 
of these drugs. 11β-HSD1 inhibition on hippocampus might decrease central feedback 
inhibition, which may cause HPA axis activation with increased GC release and 
enhancement of its effects in peripheral tissues. Moreover, non-selective compounds 
can potently inhibit 11β-HSD2 causing an apparent mineralocorticoid excessive release 
with sodium retention, hypertension and hypokalemia 
77
. Nevertheless, PPARα and 
PPARϒ agonists are able to downregulate 11β-HSD1 activity in liver and adipose 
tissue, respectively 
46,
 
96
, which can be a promising approach. Emerging data suggest 
that dietary habits have a role on 11β-HSD1 modulation. Growing evidence suggest a 
variety of potential mechanisms of action trough which polyphenols prevent disease 
97
. 
Naturally occurring 11β-HSD1 inhibitors include polyphenols, such as flavones and 
quercetin 
52,
 
98
. Coffee has been reported to have anti-diabetic effects due to its ability to 
impair hepatic gluconeogenesis and inhibit 11β-HSD1 function 52, 99. Dietary trans and 
saturated fatty acids appear to be involved in the development of MS, since they are 
able to increase local amplification of GC action in adipose tissue by upregulating 11β-
HSD1 
52,
 
100
. Sucrose promotes simultaneously a decrease in hepatic 11β-HSD1 and an 
19 
 
increase in 11β-HSD1 in adipose tissue. Dietary sucrose increases H6PDH, which in 
turn, probably increases 11β-HSD1 activity and intracellular GC. These observations 
support the notion that increased activity of 11β-HSD1 in response to sucrose ingestion 
is able to cause obesity 
52,
 
101
. The anti-obesity effect of vitamin A supplementation 
might be, in part, due to its ability to decrease 11β-HSD1 activity 102. MS seems to be 
associated with vitamin D deficiency and accordingly vitamin D status optimization 
seems to improve MS features 
103,
 
104
. A low-calcium diet alters GC metabolism leading 
to hepatic upregulation of 11β-HSD1 105; instead, a high intake of calcium, is associated 
with a low prevalence of MS 
106
. 
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Conclusion  
 
The major aim of this thesis was to review the literature concerning the involvement of 
glucocorticoids in the development of MS.  
Epidemiological and clinical studies have documented that visceral obesity and other   
comorbidities of the MS are significantly correlated with stress-related conditions such 
as adverse life events and psychosocial problems. GC, crucial mediators involved in 
stress response, are required for proper metabolic and cardiovascular control, however 
when excessively released are implicated in a variety of chronic diseases. Indeed, 
chronic stress through dysregulation of the HPA axis response, leads to 
hypercortisolemia which in turn has an important role on promoting visceral obesity, 
one of the primary mechanisms in the pathogenesis of MS. Given the continuous and/or 
repetitive exposure to emotional, professional and social stressors, subjacent to the 
modern Western lifestyle, humans are chronically under stress. The more and more 
sustained link between psychological stress and the development of MS, highlights the 
importance of coping strategies to prevent or ameliorate high levels of stress in modern 
society. Physicians might have an important role, not only on the identification of 
patients under high levels of stress, but also through counseling and support concerning 
coping strategies to handle with daily challenges. To accomplish this, it would be 
crucial to include validated tools to measure psychosocial stress levels in anamnesis.  
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Table 1. Examples of glucocorticoid-sensitive genes involved in several important 
metabolic pathways. 
(Adapted from Kyrou & Tsigos 
1
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Figure 1. The stress response leads to activation of two major neurohumoral systems, 
the hypothalamic-pituitary-adrenal axis and the sympathetic-nervous-system which, 
29 
 
through the release of cortisol and catecholamines respectively, exert crucial roles upon 
energy metabolism, ultimately leading to the development of the features of the 
metabolic syndrome.  
TG – Triglycerides; HDL - High-density lipoprotein; BP – Blood pressure  
(Adapted from Rosmond R 
34
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